hese guidelines outline a public health approach to strengthening and expanding HIV testing services (HTS). They present and discuss key updates to WHO guidelines on HTS, with a focus on new evidence, new recommendations, good practices and operational considerations that respond to the changing needs of...
In this guideline, WHO recommends that long-acting injectable cabotegravir (CAB-LA) may be offered as an additional HIV prevention option for people at substantial risk of HIV infection. CAB-LA is an injectable form of pre-exposure prophylaxis (PrEP) that has been shown to be highly effective at reducing...
As the HIV response moves to focusing on closing the remaining gaps in prevention, testing and treatment services, an evolution in the underlying routine data systems is needed to identify epidemiologic patterns and service gaps, and accelerate focused interventions.
These guidelines focus on the collec...
These guidelines provide guidance on the diagnosis of HIV infection, the care of people living
with HIV and the use of antiretroviral (ARV) drugs for treating and preventing HIV infection.
They are structured along the continuum of HIV testing, prevention, treatment and care.
This edition updates the 201...
The primary audience for this guideline is national HIV programme managers, people living
with HIV, health-care providers and policy-makers in low- and middle-income countries. This
guideline update will be a useful resource for clinicians and should help to shape the priorities
of policy-makers in devel...
WHO promotes a public health approach to programming and delivering antiretroviral therapy (ART), which has enabled access to treatment and care for people living with HIV to be scaled up in resource-limited settings.
The 2016 WHO consolidated guidelines on the use of antiretroviral drugs for treating an...
Since 2007 the World Health Organization (WHO) and the Joint United Nations
Programme on HIV/AIDS (UNAIDS) have recommended voluntary medical male
circumcision (VMMC) as an important strategy for the prevention of heterosexually
acquired HIV in men in settings where the prevalence of heterosexually trans...
The World Health Organization (WHO) convened a Guideline Development Group (GDG) meeting from 29 to 31 July 2019 to review global guidance on contraceptive eligibility for women at high risk of HIV acquisition to and determine whether revisions to the fifth edition of the Medical eligibility criteria for...
Many millions of people around the world are affected by emergencies, the majority of whom are women and children. Among them are many who are known to be living with HIV and others who may not know their HIV status. In 2016, the World Health Organization (WHO) and United Nations Children’s Fund (UNICE...
Update on recommendations on antiretroviral regimens for treating and preventing HIV infection: In 2016, WHO published the consolidated guidelines on the use of antiretroviral (ARV) drugs for treating and preventing HIV infection and recommended tenofovir disoproxil fumarate (TDF) + lamivudine (3TC) (or ...
